Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
100.57
132.77
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Jazz Pharmaceuticals PLC
Wall Street
Price Targets
JAZZ Price Targets Summary
Jazz Pharmaceuticals PLC
According to Wall Street analysts, the average 1-year price target for
JAZZ
is 180.54 USD
with a low forecast of 129.28 USD and a high forecast of 241.5 USD.
JAZZ Last Price Targets
Jazz Pharmaceuticals PLC
The latest public price target was made on Nov 18, 2024 by
Joel Beatty
from
Robert W. Baird
,
who expects
JAZZ
stock to
rise by 28%
over the next 12 months.
You can read more about this price target by viewing
the article on StreetInsider.
| Analyst | Price Target | Date | Article |
|---|---|---|---|
Joel Beatty
Robert W. Baird
|
162
USD
Upside 28% |
5 days ago
Nov 18, 2024
|
Jazz Pharmaceuticals (JAZZ) PT Raised to $162 at Baird
StreetInsider
|
Daniel Busb
RBC Capital
|
179
USD
Upside 41% |
1 month ago
Oct 23, 2024
|
Jazz Pharmaceuticals (JAZZ) PT Raised to $179 at RBC Capital
StreetInsider
|
Annabel Samimy
Stifel Nicolaus
|
230
USD
Upside 82% |
2 months ago
Sep 11, 2024
|
Stifel Reiterates Buy Rating on Jazz Pharmaceuticals (JAZZ)
StreetInsider
|
Andrea Tan
Goldman Sachs
|
169
USD
Upside 33% |
5 months ago
Jun 5, 2024
|
Goldman Sachs Starts Jazz Pharmaceuticals (JAZZ) at Buy
StreetInsider
|
|
Daniel Busb
RBC Capital
|
176
USD
Upside 39% |
6 months ago
May 2, 2024
|
Jazz Pharmaceuticals (JAZZ) PT Lowered to $176 at RBC Capital
StreetInsider
|
David Amsellem
Piper Sandler
|
188
USD
Upside 48% |
8 months ago
Mar 20, 2024
|
Jazz Pharmaceuticals (JAZZ) PT Raised to $188 at Piper Sandler
StreetInsider
|
Price Targets
Operating Income
Forecast
Operating Income Estimate
Jazz Pharmaceuticals PLC
For the last 8 years the
compound annual growth rate for
Jazz Pharmaceuticals PLC's operating income is
3%.
The projected
CAGR
for the next 3 years is
42%.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is JAZZ's stock price target?
Price Target
180.54
USD
According to Wall Street analysts, the average 1-year price target for
JAZZ
is 180.54 USD
with a low forecast of 129.28 USD and a high forecast of 241.5 USD.
What is Jazz Pharmaceuticals PLC's Revenue forecast?
Projected CAGR
6%
For the last 8 years the
compound annual growth rate for
Jazz Pharmaceuticals PLC's revenue is
14%.
The projected
CAGR
for the next 3 years is
6%.
What is Jazz Pharmaceuticals PLC's Operating Income forecast?
Projected CAGR
42%
For the last 8 years the
compound annual growth rate for
Jazz Pharmaceuticals PLC's operating income is
3%.
The projected
CAGR
for the next 3 years is
42%.
What is Jazz Pharmaceuticals PLC's Net Income forecast?
Projected CAGR
50%
For the last 8 years the
compound annual growth rate for
Jazz Pharmaceuticals PLC's net income is
3%.
The projected
CAGR
for the next 3 years is
50%.
You don't have any saved screeners yet
